

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	TBA
Filing Date	HEREWITH
Confirmation Number	TBA
First Named Inventor	A Moorman et al.
Group Art Unit	TBA 162
Examiner Name	TBA S. Kumar

Sheet	1	of	4	Attorney Docket No.	2805/5 (PHA4166.5)
-------	---	----	---	---------------------	--------------------

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
S/K	1	4,045,563	B1	Berntsson et al.	08-30-1977
	2	4,045,564	B1	Berntsson et al.	08-30-1977
	3	4,182,766	B1	Krassó et al.	01-08-1980
	4	4,248,880	B1	Krasso et al.	02-03-1981
	5	4,255,431	B1	Junggren et al.	03-10-1981
	6	4,327,102	B1	Crossley	04-27-1982
	7	4,337,257	B1	Junggren et al.	06-29-1982
	8	4,359,465	B1	Ruwart	11-16-1982
	9	4,371,537	B1	Markley et al.	02-01-1983
	10	4,394,509	B1	Crossley	07-19-1983
	11	4,472,409	B1	Senn-Bilfinger	09-18-1984
	12	4,772,619	B1	Adelstein et al.	09-20-1988
	13	5,198,552	B1	Trofimov et al.	03-30-1993
	14	5,605,919	B1	Matsumori	02-25-1997
	15	5,679,695	B1	Wassmundt	10-21-1997

Examiner Signature	S. Kumar.	Date Considered	9/6/02
--------------------	-----------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

TECH CENTER 1600/2900

AUG 28 2002

RECEIVED

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	TEA 09/885221
Filing Date	HEREWITH 6/20/02
Confirmation Number	TBA
First Named Inventor	A Moorman et al.
Group Art Unit	TEA 162
Examiner Name	TEA S. Kumar

Sheet	2	of	4	Attorney Docket No.	2805/5 (PHA4166.5)
-------	---	----	---	---------------------	--------------------

	16	5,945,425	B1	Moormann et al.	08-31-1999
--	----	-----------	----	-----------------	------------

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
SK	17	EP	130 729	A2	The Upjohn Company	01-09-1985	x
	18	EP	127 763	B1	Byk Gulden Lomberg Chemische (abstract)	12-24-1985	
	19	GB	2,134,523	A	Aktiebolaget Hassle	08-15-1984	x
	20	DE	3,415,971	A1	Gulden Lomberg Chemische Fabrik (abstract)	11-08-1984	
	21	GB	2,161,160	A	Fisons, PLC	01-08-1986	x
	22	EP	167 943	A2	Beecham Group PLC	01-15-1986	x
	23	EP	178 438	A1	Beecham Group PLC	04-23-1986	x
	24	EP	234 690	B1	Nippon Chemiphar Co., Ltd.	09-02-1986	x
	25	EP	194 458	B1	Banyu Pharmaceuticals Co., Ltd.	09-17-1986	x
	26	JP	1230560		Nippon Chemiphar Co., Ltd (abstract)	09-14-1989	
	27	EP	335 646	A1	Synphar Laboratories Inc.	10-04-1989	x
↓	28	EP	354 788	B1	Nippon Chemiphar Co., Ltd.	02-14-1990	x

Examiner Signature	S. Kumar	Date Considered	9/6/02
--------------------	----------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED

TECH CENTER 1600/2000  
AUG 28 2001

PTO/SB/08A

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

				Complete if Known	
				Application Number	TBA
				Filing Date	<del>HEREWITH</del>
				Confirmation Number	TBA
				First Named Inventor	A Moorman et al.
				Group Art Unit	<del>TBA</del> 162)
				Examiner Name	<del>TBA</del> S. Kumar
Sheet	3	of	4	Attorney Docket No.	2805/5 (PHA4166.5)

SK	29	EP	407 217	A1	Schering Corporation	01-09-1991	x
	30	WO	92/07867	A1	The Regents of the University of Michigan	05-14-1992	x
↓	31	EP	514 830	B1	Arch Development Corporation	11-25-1992	x

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
SK	32	LINDBERG et al., "Structure-activity relationships of omeprazole analogues and their mechanism of action." Trends in Pharmaceutical Sciences, 1987, pp. 399-402, Vol. 8, No. 10.	
	33	HAYASHI et al., "In Vitro and in Vivo Antiviral Activity of Scopadulcic Acid B from <i>Scoparia dulcis</i> , Scrophulariaceae, Against Herpes Simplex Virus type 1." Antiviral Research, 1988, pp. 345-354, Vol. 9.	
	34	HOLSEY et al., "Evidence for Poliovirus-Induced Cytoplasmic Alkalization iN HeLa Cells." J. of Cellular Physiology, 1990, pp. 586-591, Vol. 142.	
	35	HAYASHI et al., "Scopadulcic Acid B, a NEw Tetracyclic Diterpenoid from <i>Scoparia dulcis</i> L. Its Structure, H+, K+-Adenosine Triphosphatase Inhibitory Activity and Pharmacokinetic Behaviour in Rats." Chem, Pharm, Bull., 1990, pp. 2740-2745, Vol. 38, No. 10.	
	36	HAYASHI et al., "Antiviral Agents of Plant Origin. II. Antiviral Activity of Scopadulcic Acid B Derivatives." Chem, Pharm. Bull., 1990, pp. 239-242, Vol. 38, No. 1.	
	37	NARUSE et al., "Pumilacidin, A Complex of New Antiviral Antibiotics Production, Isolation, Chemical Properties. Structure and Biological Activity." J. Antibodies, 1990, pp. 267-280, Vol. 43, No. 3.	
↓	38	LJUNGMAN et al., "Acyclovir-Resistant Herps Simplex Virus Causing Pneumonia after Marrow Transplantation." J. Infec. Dis., 1990, pp. 244-248, Vol. 162, No. 1.	

Examiner Signature	S. Kumar	Date Considered	9/6/02
--------------------	----------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	TBA 09/885,221	AUG 9 2002
Filing Date	HEREWITH 6/20/01	RECEIVED
Confirmation Number	TBA	TECH CENTER 1600/2000
First Named Inventor	A Moorman et al.	TECH CENTER 1600/2000
Group Art Unit	TECH ) 621	TECH CENTER 1600/2000
Examiner Name	TECH S. Kurnur	TECH CENTER 1600/2000
Sheet	4	of 4
		Attorney Docket No. 2805/5 (PHA4166.5)

8X	39	GATELY et al., "Herpes Simplex Virus Type 2 Meningoencephalitis Resistant to Acyclovir in a Patient with Aids." J. Infect. Dis., 1990, pp. 711-715, Vol. 161, No. 4.	
	40	LUI et al., "The Herpes Simplex Virus 1 Gene Encoding a Protease Also Contains within Its Coding Domain the Gene Encoding the More Abundant Substrate." J. Virol., 1991, pp. 5149-5156, Vol. 65, No. 10.	
	41	WELCH et al., "A Herpesvirus Maturation Proteinase, Assembling: Identification of its Gene, Putative active site domain, and cleavage site." Proc. Natl. Acad. Sci. USA, 1991, pp. 10792-10796, Vol. 88, No. 23.	
↓	42	ALTAMIRANO et al., "Human Cytomegalovirus Infection Increases the Number of Ouabain-Binding Sites in Human Fibroblasts." Virology, 1994, pp. 151-159, Vol. 199.	

Examiner Signature	S. Kurnur	Date Considered	9/6/02
--------------------	-----------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.